Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

The Milligans were sent off on their trip by Georgia Strait Towing, which helps volunteer and fundraise for Help Fill a Dream ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue ...

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research Report) and increased the ...

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

I’m A Celebrity…Get Me Out Of Here star Reggie Bird has opened up about caring for her son with cystic fibrosis and says she ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...

Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...